pCR: hormone receptor‐positive · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐positive compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
pCR: hormone receptor‐negative · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐negative compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall survivalmedian · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Febrile neutropenia · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Diarrhoea · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pathological complete response (pCR): breast and axillary nodes compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review